Pulmonary edema on a chip

Researchers at the Harvard University have described the first disease model to emerge from the institute's organ-on-a-chip microfluidic device technology.1,2 The model of pulmonary edema could be better than culture models at predicting whether therapeutics will translate to humans.

The team already has used the lung-on-a-chip model in proof-of-concept studies to test potential pulmonary edema therapeutic candidates including GlaxoSmithKline plc's GSK2193874, an inhibitor of transient receptor potential vanilloid 4 (TRPV4; VRL2),3 and wants to expand the use of the chip to model multiple lung diseases.

GSK2193874 was also proven effective in a mouse model of pulmonary edema, validating the results that were found in the chip model (see Box 1, "TRPV4 inhibition").

The microfluidics system on a chip is about 2 cm long and mimics the alveolar-capillary interface and mechanical effects of breathing. The device is composed of two channels-a layer of human alveolar epithelial cells exposed to air and pulmonary microvascular endothelial cells exposed

Read the full 1528 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE